Gatifloxacin hydrochloride NEW
| Price | $34 |
| Package | 1g |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Gatifloxacin hydrochloride | CAS No.: 121577-32-0 |
| Purity: 99.85% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Gatifloxacin hydrochloride |
| Description | Gatifloxacin hydrochloride (AM-1155 hydrochloride) is a fourth-generation fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV. |
| Animal Research | Heptanol-induced corneal ulcers in New Zealand White rabbits (n = 41; 8 females/group) were inoculated with 10(6) CFU of Pseudomonas aeruginosa. Gatifloxacin 0.3% dosing varied among 4 groups with frequencies of 16-48 doses/day (days 1-2), 3-16 doses/day (days 3-7), and maintenance dosing of 3-4 doses/day (days 8-22). Ciprofloxacin 0.3% was administered as labeled for corneal ulcers, with 44 doses on day 1, 16 doses on day 2, and 4 doses/day on days 3-21[1] |
| In vivo | All eyes showed evidence of infection by 48 hours postinoculation with 36 of 41 eyes (87.8%) exhibiting moderate-to-severe keratitis. All eyes exhibited corneal healing by day 15, with no significant differences among groups. Three of 4 groups receiving gatifloxacin tended to have smaller fluorescein retention area scores than did the ciprofloxacin group. No eyes tested positive for Pseudomonas at the end of the study. No corneal precipitates were found following as many as 48 doses/day of gatifloxacin[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : 10 mg/mL (24.28 mM), Sonication is recommended. DMSO : 4.12 mg/mL (10 mM), Sonication is recommended. |
| Keywords | Antibiotic | AM1155 | BMS-206584 | E. coli,?Pseudomonas aeruginosa,?Micrococcus luteus | Gatifloxacin | PD-135432 | BMS 206584 | conjunctivitis | N. brasiliensis | actinomycetoma | Gatifloxacin hydrochloride | Inhibitor | S. aureus | Bacterial | inhibit | hypoglycemia | Topoisomerase | AM 1155 | Gatifloxacin Hydrochloride | diabetic | PD135432 | hyperglycemia | PD 135432 | BMS206584 | AM-1155 |
| Inhibitors Related | Neomycin sulfate | Dimethyl sulfoxide |
| Related Compound Libraries | Bioactive Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/25kg |
VIP1Y
|
Henan Suikang Pharmaceutical Co.,Ltd.
|
2024-04-25 | |
| $0.00/1kg |
VIP1Y
|
Wuhan Circle Star Chem-medical Technology Co.,Ltd
|
2025-01-09 | |
| $0.00/1kg |
VIP5Y
|
Hebei Yanxi Chemical Co., Ltd.
|
2023-09-26 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY